Home Metabolism Serine/threonin kinase inhibitor SRPIN340

research use only

SRPIN340 Serine/threonin kinase inhibitor

Cat.No.S7270

SRPIN340 is a selective SRPK inhibitor with Ki of 0.89 μM for SRPK1, showing no significant inhibitory activity against more than 140 other kinases.
SRPIN340 Serine/threonin kinase inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 349.35

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: S727001 DMSO]70 mg/mL]false]Ethanol]70 mg/mL]false]Water]Insoluble]false Purity: 99.9%
99.9

Chemical Information, Storage & Stability

Molecular Weight 349.35 Formula

C18H18F3N3O

 Storage (From the date of receipt)
CAS No. 218156-96-8 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles C1CCN(CC1)C2=C(C=C(C=C2)C(F)(F)F)NC(=O)C3=CC=NC=C3

Solubility

In vitro
Batch:

DMSO : 70 mg/mL (200.37 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 70 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Features
The only specific SRPK1 and SRPK2 inhibitor. Potential use in congenital diseases and viral diseases including HIV, HCV and HBV.
Targets/IC50/Ki
SRPK1 [1]
0.89 μM(Ki)
In vitro
SRPIN340 inhibits SR phosphorylation by SRPK in Flp-In293 cells and promotes degradation of SRp75 in a dose-dependent manner, which subsequently inhibits HIV production. This compound dose (5 mg/mL) produces no abnormalities in chromosomal structure and chromosome number of CHO cells. [1] It suppresses in a dose-dependent fashion expression of a HCV subgenomic replicon and replication of the HCV-JFH1 clone in vitro. [2]
In vivo
SRPIN340 inhibits CNV formation in a dose-dependent manner in vivo. This compound significantly decreases the protein levels of VEGF, MCP-1, ICAM-1, and consequently inhibits macrophage infiltration. [3]
References

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.